Stryker Corporation
0R2S.L
London Stock Exchange326.78
USD
+0.47
- -
Stryker Corporation
0R2S.L
(London Stock Exchange)
Recent
price
326.78
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Stryker Corporation (NYSE: SYK; LSE: 0R2S.L) develops, manufactures and markets medical technology products and services worldwide. The company operates through three primary segments—MedSurg, Neurotechnology and Orthopaedics—that serve hospitals, physicians, healthcare facilities and other customers across approximately 75 countries; it sells reconstructive implants including hip, knee, ankle and shoulder systems, Mako SmartRobotics platforms for joint replacement surgeries, trauma and extremities fixation devices such as the Gamma4 and Pangea systems, spinal implants and enabling technologies including Q Guidance systems, neurovascular products encompassing flow diverters like Surpass Elite and thrombectomy devices from Inari Medical, endoscopy equipment, surgical navigation and power tools, patient handling solutions like stretchers and beds, emergency medical devices including LIFEPAK defibrillators and AEDs, and advanced technologies such as AI-enabled software, ambient intelligence platforms from care.ai and personal protective equipment. Founded in 1941 by Dr. Homer Stryker and headquartered in Portage, Michigan, the company maintains extensive global operations with over 53,000 employees and invests heavily in R&D, exceeding $1.5 billion in 2024. Recent strategic developments include the $4.9 billion acquisition of Inari Medical in February 2025, which expanded Stryker's peripheral vascular portfolio with VTE thrombectomy solutions like InThrill and Artix systems and integrated seamlessly to drive revenue growth; completion of the Vertos Medical acquisition in October 2024 to bolster interventional pain management for lumbar spinal stenosis; and acquisitions of NICO Corporation in September 2024 for minimally invasive brain tumor removal, care.ai in the same month for AI-driven virtual care, and MOLLI Surgical in July 2024 for breast surgery localization technology. Product innovations launched in 2025 encompass the Incompass Total Ankle System with FDA clearance in June, Surpass Elite Flow Diverter in July across the U.S., South Korea and Europe, OptaBlate BVN for vertebrogenic back pain relief, and enhancements to Mako SmartRobotics for spine and shoulder procedures; the company also opened a 140,000-square-foot R&D hub focused on robotics, AI and digital health, expanded facilities in India, and completed the sale of its U.S. spinal implants business to VB Spine in April 2025. These moves underscore Stryker's commitment to high-growth segments, M&A as its primary cash deployment strategy, and innovation across orthopaedics, neurotechnology and MedSurg to enhance procedural efficiency and patient outcomes.